Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia

Marco Falcone1, Alessandro Russo2, Maddalena Giannella3

  • 1Department of Public Health and Infectious Diseases, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy; Department of Emergency Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.

Plos One
|April 11, 2015
PubMed
Abstract

Insights

A new risk score, the ARUC score, aids in identifying community-onset pneumonia caused by multidrug-resistant (MDR) bacteria. This score helps emergency department physicians select appropriate antibiotics for patients with MDR pathogens.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Clinical Microbiology

Background:

  • The rise of multidrug-resistant (MDR) bacteria necessitates identifying risk factors for community-acquired resistant pathogens.
  • Community-onset pneumonia (COP) poses a significant challenge due to the increasing prevalence of MDR organisms.

Purpose of the Study:

  • To analyze clinical features of patients with COP due to MDR pathogens.
  • To evaluate existing scoring tools for MDR pathogen identification in pneumonia.
  • To develop a bedside risk score for early identification of MDR pneumonia in the Emergency Department (ED).

Main Methods:

  • An observational, prospective study included 900 consecutive patients with community-acquired pneumonia.
  • A logistic regression model identified key predictors for MDR pneumonia.
  • The developed ARUC score was validated on an external cohort of 929 patients.

Main Results:

  • The ARUC score incorporates risk factors for healthcare-associated pneumonia (HCAP), bilateral infiltrates, pleural effusion, and respiratory impairment (PaO2/FiO2 ratio).
  • The ARUC score demonstrated good discrimination (AUC 0.76) and calibration, outperforming the HCAP definition in predicting MDR etiology.
  • Validation confirmed the score's performance (AUC 0.68).

Conclusions:

  • Emergency department physicians should utilize simple risk scores like the ARUC score.
  • The ARUC score assists in selecting appropriate antibiotic regimens for MDR pneumonia.
  • An individualized approach using risk scores can guide empirical broad-spectrum antibiotic therapy decisions.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
141
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
57
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
64